This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by McCullough, P. A Articles by Hudson, M. P Search for Related Content PubMed PubMed Citation Articles by McCullough, P. A Articles by Hudson, M. P Pubmed/NCBI databases Medline Plus Health Information Heart Disease in Women Heart Diseases Social Bookmarking                         What's this?

Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease

William Beaumont Hospital, Divisions of Cardiology, Nutrition and Preventive Medicine, Royal Oak, MI, Henry Ford Health System, pmc975@ yahoo.com

Keisha R Sandberg

Henry Ford Heart and Vascular Institute

Jerry Yee

Henry Ford Hospital, Department of Internal Medicine, Division of Hypertension and Nephrology, Beaumont Health Center, 4949 Coolidge, Royal Oak, MI 48073, USA

Michael P Hudson

Henry Ford Heart and Vascular Institute

Hypothesis/Introduction

The risks and benefits of angiotensin-converting enzyme (ACE) inhibitors in patients with end-stage renal disease (ESRD) after cardiac events are unknown. We sought to determine the independent effect of ACE inhibitors (ACE-I) on long-term mortality in ESRD patients after cardiac events.

Materials and methods

We analysed a prospective coronary care unit registry and identified 527 ESRD patients, 368 with complete data on medications prescribed, over eight years at a single, tertiary centre.

Results

The overall mean age was 64.4 13.8 years with 54.9% men, and 59.2% African-American. A total of 143/386 (37.0%) were prescribed ACE-I during the hospital stay for cardiac reasons, including congestive heart failure (CHF) 52.8% and acute coronary syndromes (ACS) 47.2%. There were no significant differences in the rates of hypotension or arrhythmias in those who were treated with ACE-I versus those who were not. Survival analysis over three years, adjusted for known confounders, demonstrated a 37% reduction in all-cause mortality in those who received ACE-I, (p=0.0145).

Conclusions

In the setting of coronary care unit admission for CHF and ACS, ESRD patients selected for ACE-I, did not have increased rates of adverse haemodynamic or arrhythmic complications. The use of ACE-I conferred an independent mortality reduction over long-term follow-up.

Key Words: coronary care unit • end-stage renal disease • angiotensin-converting enzyme inhibitors • survival • arrhythmias • complications

Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 3, 188-191 (2002)
DOI: 10.3317/jraas.2002.040


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Suzuki Therapeutic efficacy of renin--angiotensin blockade in patients receiving dialysis Therapeutic Advances in Cardiovascular Disease, October 1, 2009; 3(5): 397 - 405. [Abstract] [PDF]

				W. Fang, D. G. Oreopoulos, and J. M. Bargman Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3704 - 3710. [Abstract] [Full Text] [PDF]

				A. G. Zenovich and D. A. Taylor CELL THERAPY IN KIDNEY DISEASE: CAUTIOUS OPTIMISM... BUT OPTIMISM NONETHELESS Perit. Dial. Int., June 1, 2007; 27(Supplement_2): S94 - S103. [Abstract] [Full Text] [PDF]

				P. A. McCullough Coronary Artery Disease Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 611 - 616. [Abstract] [Full Text] [PDF]